

WEDNESDAY, 13<sup>th</sup> NOVEMBER 2019 COMMENCING 10:30 AM  
AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,  
CULVERHOUSE CROSS, CARDIFF CF5 6DH

**AGENDA**

Enclosure

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

1/AWMSG/1119

*To protect commercial confidentiality the following appraisal will be held in private*

5. **Appraisal 1: Limited Submission (PAS)**  
**Dupilumab (Dupixent®)** for the treatment of moderate-to-severe atopic dermatitis in adolescents ≥12 to <18 years who are candidates for systemic therapy

2/AWMSG/1119  
Appendices

*The meeting will now open to the public*

6. Chairman's report (verbal update)

7. **Appraisal 2: Full Submission**  
**Melatonin (Slenyto®)** for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient

3/AWMSG/1119  
Appendices

8. **Appraisal 3: Limited Submission**  
**Cefepime (Renapime®)** for the treatment of infections caused by bacteria that are cefepime-sensitive including lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis; uncomplicated and complicated urinary tract infections, including pyelonephritis; skin and subcutaneous infections; intra-abdominal infections, including peritonitis and biliary tract infections; gynaecological infections; bacterial meningitis in infants and children; in combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection; treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents

4/AWMSG/1119  
Appendices

9. **Appraisal 4: Limited Submission**  
**Diamorphine hydrochloride (Ayendi®)** for the treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Diamorphine hydrochloride nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring

5/AWMSG/1119  
Appendices

10. **Any other business**

**Date of next meeting – Wednesday, 11<sup>th</sup> December 2019 in Cardiff**